biologic

PENMENVY

Meningococcal Groups A, B, C, W and Y Vaccine

Loss of exclusivityFebruary 2037projected — 12-year biologic exclusivity estimate
CompanyGlaxoSmithKline Biologicals

Drug detail

Brand namePENMENVY
Active ingredientMeningococcal Groups A, B, C, W and Y Vaccine
Strength25UG/0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalFebruary 2025
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

PENMENVY patent cliff — loss of exclusivity February 2037 | CliffBio